Award
NIH Reporter #5U01AI184132-03
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage
Recipient
Not specified
Award Amount
$958,627.00
Ceiling
$958,627.00
Awarded
August 18, 2026
Identifier
5U01AI184132-03
This award funds a clinical trial to determine optimal busulfan dosing in infants with SCID, focusing on immune system recovery and safety, supported by NIH/NIAID.
Description
A clinical trial testing low dose busulfan in infants with SCID to evaluate immune reconstitution and safety, funded by NIH/NIAID. The study includes multiple hypotheses related to immune response, chimerism, and vaccine response, involving multiple centers and complex immunological assessments.